Our strategy has profound relevance for GBM patients and will provide a rationale for translational feasibility and insight into the novel epigenetic reprogramming mechanisms and contribute towards optimal design of impactful trials for MGMT-UM GBMs that do not have good therapeutic options. This evidence concerns the gene MGMT and glioblastoma.